Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian Webthal project

Combined chelation therapy with deferasirox and deferoxamine in thalassemia

(2012) Ashutosh Lal et al.   BLOOD CELLS MOLECULES AND DISEASES

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

(2012) D. J. Pennell et al.   HAEMATOLOGICA

Mechanisms of Renal Disease in  -Thalassemia

(2012) K. M. Musallam et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

(2011) M. D. Cappellini et al.   BLOOD

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications

(2011) Kallistheni Farmaki et al.   BLOOD CELLS MOLECULES AND DISEASES

Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies

(2011) Ersi Voskaridou et al.   BRITISH JOURNAL OF HAEMATOLOGY

Iron Overload Cardiomyopathy in Clinical Practice

(2011) Dimitrios T. Kremastinos et al.   CIRCULATION

On T2* Magnetic Resonance and Cardiac Iron

(2011) John-Paul Carpenter et al.   CIRCULATION

Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years

(2011) Yves Deugnier et al.   GASTROENTEROLOGY

Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias

(2011) P. J. Ho et al.   INTERNAL MEDICINE JOURNAL

Impact of magnetic resonance imaging on cardiac mortality in thalassemia major

(2011) Giorgos Chouliaras et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Impact of Iron Assessment by MRI

(2011) J. C. Wood   Hematology-American Society of Hematology Education Program

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

(2010) Ali Taher et al.   ACTA HAEMATOLOGICA

Deferiprone

(2010) Antonio Piga et al.   Annals of the New York Academy of Sciences

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

(2010) J. C. Wood et al.   BLOOD

Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone

(2010) Maria Eliana Lai et al.   BLOOD CELLS MOLECULES AND DISEASES

Renal complications in transfusion-dependent beta thalassaemia

(2010) Claudio Ponticelli et al.   BLOOD REVIEWS

Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit

(2010) Vassilios Ladis et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Continued improvement in myocardial T2* over two years of deferasirox therapy in  -thalassemia major patients with cardiac iron overload

(2010) D. J. Pennell et al.   HAEMATOLOGICA

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

(2010) A. Pepe et al.   HAEMATOLOGICA

International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers

(2010) Paul Kirk et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years

(2010) Arunee Jetsrisuparb et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

The influence of treatment in specialized centers on survival of patients with thalassemia major

(2009) Gian Luca Forni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

(2009) Aurelio Maggio et al.   BLOOD CELLS MOLECULES AND DISEASES

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

(2009) Ali Taher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone

(2009) P. T. Telfer et al.   HAEMATOLOGICA

Complications and treatment of patients with  -thalassemia in France: results of the National Registry

(2009) I. Thuret et al.   HAEMATOLOGICA

Update on Survival in Thalassemia Major

(2009) Paul Telfer   HEMOGLOBIN

Non-invasive assessment of tissue iron overload

(2009) R. Fischer et al.   Hematology-American Society of Hematology Education Program

Survival and Complications of Beta-Thalassemia in Lebanon

(2008) K. Charafeddine et al.   ACTA HAEMATOLOGICA

Longitudinal analysis of heart and liver iron in thalassemia major

(2008) L. J. Noetzli et al.   BLOOD

Cardiac iron across different transfusion-dependent diseases

(2008) John C. Wood   BLOOD REVIEWS

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders

(2008) E. Angelucci et al.   HAEMATOLOGICA

Challenges Associated With Prolonged Survival of Patients With Thalassemia: Transitioning From Childhood to Adulthood

(2008) K. Musallam et al.   PEDIATRICS